| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5546828 | Actualités Pharmaceutiques | 2017 | 8 Pages |
Abstract
New anti-diabetic drugs are regularly becoming available, in particular Glucagon-like peptide-1 (GLP-1) receptor agonists. In 2016, a new selective oestrogen receptor modulator, acting in the uterus as an oestrogen receptor antagonist, which considerably reduces the risk caused by oestrogen of endometrial hyperplasia in women with an intact uterus, have also arrived on the market.
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
Jacques (Professeur des Universités), Sébastien (Professeur des Universités),